Advertisement

Advertisement

CPRX Stock Latest News

Solaris to replace Catalyst Pharmaceuticals in the S&P 600 at open on 7/15

The FlySolaris to replace Catalyst Pharmaceuticals in the S&P 600 at open on 7/15

Catalyst Pharma Shareholders Approve Angelini Merger Agreement

PremiumCompany Announcements

Catalyst Pharma Shareholders Approve Angelini Merger Agreement

14d ago

Catalyst Pharma reports positive Phase 1 AGAMREE results

PremiumCompany Announcements

Catalyst Pharma reports positive Phase 1 AGAMREE results

22d ago

Catalyst Pharma Gains FTC Clearance for Angelini Merger

PremiumCompany Announcements

Catalyst Pharma Gains FTC Clearance for Angelini Merger

29d ago

Catalyst Pharmaceuticals Sets July 2026 Vote on $31.50-per-Share Angelini Pharma Buyout

PremiumCompany Announcements

Catalyst Pharmaceuticals Sets July 2026 Vote on $31.50-per-Share Angelini Pharma Buyout

1M ago

Catalyst Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright

PremiumThe FlyCatalyst Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright

2M ago

Catalyst Pharmaceuticals reports Q1 non-GAAP EPS 79c, consensus 64c

The Fly

Catalyst Pharmaceuticals reports Q1 non-GAAP EPS 79c, consensus 64c

2M ago

Catalyst Pharmaceuticals not providing forward-looking guidance

The Fly

Catalyst Pharmaceuticals not providing forward-looking guidance

2M ago

Catalyst Pharma Reports Higher Revenue, Suspends Earnings Guidance

PremiumCompany Announcements

Catalyst Pharma Reports Higher Revenue, Suspends Earnings Guidance

2M ago

CPRX Upcoming Earnings Report: What to Expect?

PremiumPre-Earnings

CPRX Upcoming Earnings Report: What to Expect?

2M ago

Catalyst Pharmaceuticals downgraded to Neutral from Buy at Citi

PremiumThe Fly

Catalyst Pharmaceuticals downgraded to Neutral from Buy at Citi

2M ago

Catalyst Pharmaceuticals downgraded to Neutral from Outperform at Baird

PremiumThe Fly

Catalyst Pharmaceuticals downgraded to Neutral from Outperform at Baird

3M ago

Catalyst Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer

PremiumThe FlyCatalyst Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer

3M ago

Catalyst Pharma Settles Firdapse Patent Litigation With Hetero

Company Announcements

Catalyst Pharma Settles Firdapse Patent Litigation With Hetero

3M ago

Catalyst Pharmaceuticals downgraded to Equal Weight from Overweight at Stephens

The Fly

Catalyst Pharmaceuticals downgraded to Equal Weight from Overweight at Stephens

3M ago

Catalyst Pharmaceuticals to be acquired by Angelini Pharma for $31.50 per share

PremiumThe Fly

Catalyst Pharmaceuticals to be acquired by Angelini Pharma for $31.50 per share

3M ago

Analyst Initiates Buy on Catalyst Pharma, Citing M&A Appeal, Rare Disease Growth and $35 Price Target Backed by Strong Balance Sheet

PremiumRatings

Analyst Initiates Buy on Catalyst Pharma, Citing M&A Appeal, Rare Disease Growth and $35 Price Target Backed by Strong Balance Sheet

3M ago

Angelini exploring acquisition of Catalyst Pharmaceuticals, Bloomberg says

PremiumThe Fly

Angelini exploring acquisition of Catalyst Pharmaceuticals, Bloomberg says

3M ago

Catalyst Pharmaceuticals trading resumes

PremiumThe Fly

Catalyst Pharmaceuticals trading resumes

3M ago

Catalyst Pharmaceuticals trading halted, volatility trading pause

PremiumThe FlyCatalyst Pharmaceuticals trading halted, volatility trading pause

3M ago

Catalyst Pharma Patent Trial Against Hetero USA Delayed

Company Announcements

Catalyst Pharma Patent Trial Against Hetero USA Delayed

4M ago

Catalyst Pharmaceutical Partners Signals Confident Growth Path

Company Announcements

Catalyst Pharmaceutical Partners Signals Confident Growth Path

4M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >